| ACS Chemical Neuroscience Molecule Spotlight on RG1678. | |
| | |
MedLine Citation:
|
PMID: 22860161 Owner: NLM Status: PubMed-not-MEDLINE |
Abstract/OtherAbstract:
|
RG1678 is a glycine transporter-1 inhibitor currently in Phase III trials for the treatment of the negative symptoms of schizophrenia and is being developed by Roche (in combination with Chugai). Recent Phase II data shows that RG1678 is effective in reducing the negative symptoms when given in combination with second generation antipsychotics. |
| | |
Authors:
|
Corey R Hopkins |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: ACS chemical neuroscience Volume: 2 ISSN: 1948-7193 ISO Abbreviation: ACS Chem Neurosci Publication Date: 2011 Dec |
Date Detail:
|
Created Date: 2012-08-03 Completed Date: 2012-08-23 Revised Date: 2012-12-21 |
Medline Journal Info:
|
Nlm Unique ID: 101525337 Medline TA: ACS Chem Neurosci Country: United States |
Other Details:
|
Languages: eng Pagination: 685-6 Citation Subset: - |
Affiliation:
|
Department of Pharmacology and Chemistry, Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, Vanderbilt University , Nashville, Tennessee 37232-6600, United States. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Phosphorylation of ?-Synuclein at Y125 and S129 alters its metal binding properties: implications fo...
Next Document: Detection of multiple sclerosis from exhaled breath using bilayers of polycyclic aromatic hydrocarbo...